Zydus Cadila has received the final approval from the USFDA to market Teriflunomide Tablets (US RLD- AUBAGIO), 7 mg and 14 mg. It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.
Teriflunomide is used to treat relapsing forms of multiple sclerosis (MS). It is not a cure for MS but is thought to work by decreasing certain immune system cells (lymphocytes) which can attack the nerves in brain and spinal cord. This helps decrease the number of flare-ups (relapses) and may help slow down physical problems caused by MS.
The group now has 237 approvals and has so far filed over 340 ANDAs since the commencement ofthe filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.363.9 as compared to the previous close of Rs. 356.25. The total number of shares traded during the day was 90309 in over 1280 trades.
The stock hit an intraday high of Rs. 365.5 and intraday low of 353.65. The net turnover during the day was Rs. 32612856.